Loss of fragile site-associated tumor suppressor promotes antitumor immunity via macrophage polarization

Lijuan Zhang1,8, Kai Zhang1,8, Jieyou Zhang1,8, Jinrong Zhu2, Qing Xi1, Huafeng Wang3, Zimu Zhang1, Yingnan Cheng1, Guangze Yang1, Hongkun Liu1, Xiangdong Guo1, Dongmei Zhou1, Zhenyi Xue1, Yan Li1, Qi Zhang4, Yurong Da1, Li Liu5, Zhinan Yin6, Zhi Yao1 & Rongxin Zhang1,7

Common fragile sites (CFSs) are specific breakage-prone genomic regions and are present frequently in cancer cells. The (E2-independent) E3 ubiquitin-conjugating enzyme FATS (fragile site-associated tumor suppressor) has antitumor activity in cancer cells, but the function of FATS in immune cells is unknown. Here, we report a function of FATS in tumor development via regulation of tumor immunity. Fats−/− mice show reduced subcutaneous B16 melanoma and H7 pancreatic tumor growth compared with WT controls. The reduced tumor growth in Fats−/− mice is macrophage dependent and is associated with a phenotypic shift of macrophages within the tumor from tumor-promoting M2-like to antitumor M1-like macrophages. In addition, FATS deficiency promotes M1 polarization by stimulating and prolonging NF-κB activation by disrupting NF-κB/IkBα negative feedback loops and indirectly enhances both CD4+ T helper type 1 (Th1) and cytotoxic T lymphocyte (CTL) adaptive immune responses to promote tumor regression. Notably, transfer of Fats−/− macrophages protects mice against B16 melanoma. Together, these data suggest that FATS functions as an immune regulator and is a potential target in cancer immunotherapy.

1 Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. 2 Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China. 3 School of Life Science, Shanxi Normal University, Linfen, China. 4 Institute of Integrative Medicines for Acute Abdominal Diseases, Nankai Hospital, Tianjin, China. 5 Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 6 The First Affiliated Hospital, Biomedical Translation Research Institute and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, China. 7 Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin, China. 8 These authors contributed equally: Lijuan Zhang, Kai Zhang, Jieyou Zhang. ✉email: rxzhang@gdpu.edu.cn
The tumor microenvironment (TME) contains innate and adaptive immune cells that recognize and destroy tumors. However, tumors not only manage to escape the host immune system but also benefit from infiltrating immune cells by modifying the functions of these cells to establish an immunosuppressive microenvironment that is favorable for tumor progression. During all stages of tumor development, tumor-associated macrophages (TAMs) are present in the TME and play pivotal roles in both antitumor and protumor effects depending on their classically activated M1 or alternatively activated M2 subtype, respectively. Monocyte-derived macrophages polarize into either the M1 or the M2 subtype depending on environmental cues. In general, M1 macrophages are potent antitumor cells that highly express MHCII and inducible nitric oxide synthase (NOS2), are efficient producers of inflammatory cytokines (interleukin-1β (IL-1β), IL-6, IL-12), and participate as inductor and effector cells in polarized Th1 responses. However, M2 macrophages display protumor functions. Circulating monocytes are recruited by tumor cells and adopt features common to M2-like macrophages. M2-like TAMs play a key role in tumor growth and progression by producing molecules to promote angiogenesis as well as the survival and metastasis of tumor cells. Moreover, TAMs suppress effective antitumor immune responses by expressing immunosuppressive molecules (IL-10, transforming growth factor-β (TGF-β)). Either ablation of TAMs or switching of macrophages into the antitumor M1-like phenotype results in a significant reduction in tumor growth. Based on current studies, an immunotherapeutic strategy targeting M1/M2 macrophage polarization in the TME may be effective and promising.

As an inherent component of chromosomal structure, common fragile sites (CFs) are evolutionarily conserved and breakage-prone genomic regions that exist in all individuals. CFs preferentially form gaps or breaks on metaphase chromosomes upon replication stress and are frequently found in cancer cells. Current studies show that instability-induced alterations at fragile sites contribute to tumorigenesis, considering that genomic instability is a hallmark of cancer. However, studies on fragile site functions in immunity are limited, such that GO antitumor cells that highly express MHCII and inducible nitric oxide synthase (NOS2) are efficient producers of inflammatory cytokines (interleukin-1β (IL-1β), IL-6, IL-12), and participate as inductor and effector cells in polarized Th1 responses. However, M2 macrophages display protumor functions. Circulating monocytes are recruited by tumor cells and adopt features common to M2-like macrophages. M2-like TAMs play a key role in tumor growth and progression by producing molecules to promote angiogenesis as well as the survival and metastasis of tumor cells. Moreover, TAMs suppress effective antitumor immune responses by expressing immunosuppressive molecules (IL-10, transforming growth factor-β (TGF-β)). Either ablation of TAMs or switching of macrophages into the antitumor M1-like phenotype results in a significant reduction in tumor growth. Based on current studies, an immunotherapeutic strategy targeting M1/M2 macrophage polarization in the TME may be effective and promising.

As an inherent component of chromosomal structure, common fragile sites (CFs) are evolutionarily conserved and breakage-prone genomic regions that exist in all individuals. CFs preferentially form gaps or breaks on metaphase chromosomes upon replication stress and are frequently found in cancer cells. Current studies show that instability-induced alterations at fragile sites contribute to tumorigenesis, considering that genomic instability is a hallmark of cancer. However, studies on fragile site functions in immunity are limited, such that GO analysis showed that the terms related to immune response were significantly overrepresented in genes located at fragile sites. Functional characterization of fragile site-connected components indicated that a number of immune-related genes are associated with fragile sites, for example, LIF, which can induce macrophage differentiation. However, limited experimental data have shown the link between CFs and immune function to date. C10orf90 (also called D7Ertd443e in mice) is a fragile-site-associated gene that maps to the common fragile site FRA10F on chromosome 10q26 in the human genome. Previous studies identified it as fragile site-associated tumor suppressor (FATS) because the gene was susceptible to breakage in an irradiation (IR)-induced mouse tumor model. However, current studies on FATS have mainly focused on evaluating its mutation and potential functions in cancer cells, including non-small-cell lung cancer (NSCLC), breast cancer, and ovarian cancer cells. There are few studies on FATS and its functional characterization in immune cells, which play crucial roles in tumor formation and growth, that have been well established to date.

In this work, we utilize Fats−/− mice to explore the role of FATS in tumor immunity. FATS deficiency reduces tumor growth in vivo and increases the survival of mice. We demonstrate that FATS functions as a regulator of macrophage polarization both in vitro and in vivo. Furthermore, the polarization of macrophages toward an antitumor phenotype induced by FATS deficiency correlates with the enhanced antitumor T cell activity within the TME. Our results suggest that FATS functions as a molecular switch that regulates antitumor immunity. We also provide insights into the role of FATS in cancer development.

**Results**

**FATS deficiency prevents tumor growth in vivo.** To investigate whether FATS plays an important role in tumor growth, B16 melanoma cells were injected subcutaneously into Fats−/− or WT mice. Compared to WT mice, Fats−/− mice exhibited reduced tumor growth and prolonged survival (Fig. 1a–c). Similar results were observed in Fats−/− mice injected subcutaneously with H7 pancreatic cancer cells (Fig. 1d–f). Moreover, we observed a significant reduction in lung metastasis of B16 tumors after induction of FATS deficiency, and Fats−/− mice exhibited prolonged survival in the metastasis model (Fig. 1g–i). Collectively, these data demonstrate that FATS deficiency impairs tumor growth in vivo and prolongs animal survival.

**FATS deficiency inhibits M2-like TAM function within tumors.** Studies over the past two decades have revealed that the TME is a determinant of tumor progression equally important to the tumor itself. Bioinformatic analysis revealed that CFs are associated with immune regulation. Thus, we speculated that the delayed tumor growth in Fats−/− mice might be associated with changes in the tumor immune microenvironment caused by FATS deficiency. As expected, quantification of tumor-infiltrating immune cells revealed that FATS deficiency significantly reduced the fractions of total myeloid cells (CD11b+) and TAMs (Ly6G−CD11b+F4/80+) but did not alter the fractions of monocytes (Ly6G−CD11b+Ly6C+) and granulocytes (CD11b+Ly6G+) (Fig. 2a) as determined using the gating strategy shown in Supplementary Fig. 1a. Notably, FATS deficiency upregulated MHCII expression but decreased CD206 expression in TAMs (Fig. 2b), suggesting that FATS deficiency increases the M1-like macrophage fraction among TAMs. In addition, we analyzed macrophages in the spleens and lungs of mice with B16 metastases and found that Fats−/− splenic and alveolar macrophages also displayed higher MHCII expression than control cells (Fig. 2c), suggesting M1 skewing. Furthermore, the mRNA expression of M1 and M2 markers was examined in TAMs isolated from Fats−/− and WT B16 tumors. Higher expression of M1 markers (Il12, Il1b, Il6, and Nos2) was detected in Fats−/− TAMs, whereas the expression of M2 markers (Il10, Tgfb, and Mrc1) was reduced (Fig. 2d). Similar results were observed in Fats−/− tumor samples compared with WT tumors (Supplementary Fig. 2). Moreover, in B16 tumor-bearing Fats−/− mice, serum levels of proinflammatory cytokines (IFN-γ, IL-12, and IL-1β) were increased, while the level of the anti-inflammatory cytokine IL-10 was significantly decreased (Fig. 2e). We subsequently tested the suppressive function of TAMs derived from B16 tumor-bearing Fats−/− and WT mice on T cell proliferation, as a major pathogenic activity of TAMs is suppression of antitumor immune responses. The proliferation of T cells was inhibited by B16 tumor-bearing WT TAMs compared with FATS-deficient TAMs or in the absence of TAMs, suggesting that the suppression of T cells by TAMs was relieved in B16 tumor-bearing Fats−/− mice (Fig. 2f, g). Together, these results demonstrate that FATS deficiency significantly changes the M1/M2 ratio in TAMs, leading to a less immunosuppressive TME.

**Reduced tumor growth in Fats−/− mice is macrophage dependent.** To investigate whether FATS deficiency in macrophages is required for tumor repression, WT and Fats−/− mice that had been prechallenged with B16 cells were serially treated with clodronate liposomes (Fig. 3a), which deplete macrophages from tissues. The efficiency of macrophage depletion was...
confirmed by analyzing CD11b^+ F4/80^+ cells in the spleen and tumors (Fig. 3b). In accordance with previous reports, we observed that macrophage depletion inhibited B16 tumor growth in WT mice. In contrast, macrophage depletion in Fats^−/− mice did not inhibit tumor growth but instead promoted tumor growth to a certain extent (Fig. 3c–e). These results indicate that FATS deficiency reverses the function of macrophages in tumors, switching them from a protumor phenotype to an antitumor phenotype. When comparing tumor growth between the Fats^−/− and WT groups, both of which were treated with clodronate liposomes, we observed that FATS deficiency did not delay B16 tumor growth in the absence of macrophages (Fig. 3f–g), confirming that the reduced tumor growth in Fats^−/− mice is macrophage dependent. Notably, the number of B16 tumor-infiltrating T cells was substantially increased in WT mice but was not significantly changed in Fats^−/− mice after macrophage depletion (Fig. 3h, i), further indicating that FATS deficiency relieves immunosuppression in a macrophage-dependent manner.

**FATS blockade produces an intrinsic bias toward M1 polarization.** To investigate whether FATS directly regulates macrophage polarization, we analyzed mRNA and protein expression in primary mouse macrophages. First, RNA-sequencing analysis showed that the expression of genes associated with antigen presentation, T cell activation, and innate immunity was elevated...
in Fats−/− BMDMs, while the expression of genes associated with immune suppression and chemoattraction was decreased in vitro under basal (in the presence of M-CSF) conditions (Fig. 4a), further confirming the significant changes in key M1/M2 markers on TAMs between WT and Fats−/− mice-bearing melanoma tumors (Fig. 2d). Moreover, mRNA and protein levels were analyzed in vitro in primary mouse macrophages stimulated with lipopolysaccharide (LPS) or IL-4. The expression of proinflammatory cytokines that are associated with M1 macrophages was upregulated in Fats−/− BMDMs. In contrast, the expression of genes associated with M2 macrophages (Arg1 and Ym1) was inhibited (Fig. 4b, c and Supplementary Fig. 3a–c). Similar results
were observed in Fats\(^{-/-}\) peritoneal macrophages (Supplementary Fig. 3d). In addition, the expression of CD80/86 and MHCI/II on BMDMs from WT and Fats\(^{-/-}\) mice was examined under different polarization conditions (Fig. 4d, e). B16 cell culture supernatant was used to culture BMDMs for 24 and 48 h (Fig. 4d). Fats\(^{-/-}\) BMDMs showed a higher expression of CD80/86 and MHCI II than WT BMDMs after 24 h. Notably, MHCI and CD86 expression was significantly decreased in WT BMDMs after 48 h, while there was no obvious change in Fats\(^{-/-}\) BMDMs, suggesting that FATS deficiency increases M1 polarization under tumor conditions. Consistent with these results, under TAM, M2, and M1 polarization conditions (Fig. 4e), Fats\(^{-/-}\) BMDMs still had a higher expression of MHCI and CD86 than WT BMDMs, indicating the effect of FATS deficiency on skewing BMDMs toward M1 polarization. In addition, FATS deficiency enhanced the expression of MHCI on peritoneal macrophages (Supplementary Fig. 3e). Furthermore, silencing FATS in CD14\(^{+}\) monocyte-derived human macrophages increased the expression of M1-type proteins (HLA-DR and CD86) (Fig. 4g) and decreased that of M2-type genes (MRC1, TGFB, ARG1, and IL10) (Fig. 4h). The knockdown efficiency of FATS small interfering RNA (siRNA) was confirmed by Quantitative Real-time PCR, as shown in Fig. 4f. Collectively, these results confirm that FATS deficiency promotes macrophage polarization toward the M1-like phenotype.

**FATS deficiency sustains NF-κB activity.** LPS activates several signaling pathways, including the NF-κB, ERK, JNK, and p38/MAPK pathways as well as the signal transducer and activator of transcription (STAT) pathway in macrophages.\(^{27,28}\) To investigate the mechanism of macrophage polarization under FATS-deficient conditions, intracellular TLR4 signaling was detected using western blot analysis. LPS induced p38/MAPK, ERK, JNK, NF-κB, and STAT activation by phosphorylation in both WT and Fats\(^{-/-}\) macrophages (Fig. 5a and Supplementary Fig. 4a, b). However, p-p65 activity was significantly enhanced in Fats\(^{-/-}\) macrophages compared with WT macrophages after LPS stimulation (Fig. 5a), whereas Fats\(^{-/-}\) macrophages displayed levels of p-p38, p-ERK, p-JNK, p-STAT1, and p-STAT3 similar to those in WT macrophages after LPS stimulation (Supplementary Fig. 4a, b). Similarly, increased p-p65 activity was also observed in Fats\(^{-/-}\) peritoneal macrophages compared with WT peritoneal macrophages (Supplementary Fig. 4c). Phosphorylation of the p65 subunit of NF-κB helps stabilize NF-κB in the nucleus for gene transcription.\(^{29}\) Indeed, immunofluorescence staining showed that FATS deletion hampered the translocation of p65 from the nucleus to the cytoplasm in macrophages after LPS stimulation (Fig. 5b, c). We next examined the effect of FATS deletion on the stability and phosphorylation of proteins that regulate NF-κB activity, including IkBa and inhibitory kappa B kinase β (IKKβ). IKKβ promotes the degradation of IkBa, leading to the release of NF-κB from the inhibitory IkBa-NF-κB complex.\(^{30}\) In LPS-stimulated Fats\(^{-/-}\) macrophages, FATS deletion increased the phosphorylation of IkBa, whereas there was no significant difference in the phosphorylation of IKKβ (Fig. 5d). To further verify the effect of FATS deletion on the NF-κB signaling pathway, the phosphorylation state of p65, IkBa, and IKKβ was detected in RAW264.7 cells transduced with a lentiviral expression construct encoding mouse FATS. We observed that phosphorylation of IkBa and p65 but not IKKβ was inhibited in FATS-expressing macrophages during the LPS response compared with that in control cells (Fig. 5e). These results indicate that FATS is an inhibitor of the TLR4-NF-κB activation pathway, and this inhibition may be associated with the regulation of IkBa phosphorylation.

To further explore the mechanism by which FATS regulates the NF-κB signaling pathway, degradation of endogenous IkBa was assessed in Fats\(^{-/-}\) and WT macrophages at different time points after LPS treatment. We observed that degradation of IkBa was enhanced in LPS-stimulated Fats\(^{-/-}\) macrophages compared with WT macrophages (Fig. 5f). In addition, the mRNA levels of IkBa were examined in Fats\(^{-/-}\) and WT macrophages under basal conditions or after stimulation with LPS. FATS deletion did not alter the IkBa mRNA level under basal conditions. Moreover, the mRNA level of IkBa was increased in Fats\(^{-/-}\) macrophages after LPS stimulation for 30 min (Fig. 5g), further confirming our previous conclusion that FATS deletion enhances the NF-κB transcriptional activity that triggers IkBa gene transcription. We also observed that the protein level of IkBa was higher in RAW264.7 cells infected with a lentiviral expression construct encoding mouse FATS than in control cells (Supplementary Fig. 4d). These results indicated that FATS suppressed the NF-κB activation pathway by inhibiting the degradation of IkBa.

It has been reported that FATS catalyzes the polyubiquitination of p53 mainly as K63-linked nonlinear polyubiquitination.\(^{31}\) Herein, we detected the effect of FATS on K63-linked polyubiquitination of IkBa; however, we did not observe any obvious differences in K63-linked polyubiquitination of IkBa between Fats\(^{-/-}\) cells and control cells (data not shown), indicating that FATS dysregulation has no impact on K63-linked polyubiquitination of IkBa. Interestingly, we found that loss of FATS increased but overexpression of FATS significantly decreased the level of K48-linked polyubiquitination of IkBa (Fig. 5h). Furthermore, the co-immunoprecipitation (co-IP) assay showed that FATS interacts with the N-terminal signal response domain (SRD) of IkBa (Fig. 5i). The SRD can receive the phosphorylation signal and subsequent K48-linked ubiquitination signal, further mediating the degradation of IkBa by targeting the protein to the proteasome.\(^{32}\) In addition, treatment with BAY11-7082, a specific NF-κB inhibitor, suppressed the inflammatory phenotype observed in Fats\(^{-/-}\) macrophages (Fig. 5i). Therefore, our data support the idea that FATS represses the K48-linked ubiquitination of IkBa by inhibiting the phosphorylation of IkBa by upstream kinases, subsequently promoting cytoplasmic accumulation of IkBa and repressing the transcriptional activity of NF-κB. Loss of FATS in macrophages enhanced the transcriptional activity of NF-κB via promotion of K48-linked
polyubiquitination of IκBα and nuclear accumulation of NF-κB (Fig. 5k).

Fats<sup>−/−</sup> macrophages promote Th1 responses. One of the hallmarks of M1 macrophage polarization is the acquisition of antigen-presenting features, which leads to efficient Th1 responses<sup>33,34</sup>. To investigate whether FATS deficiency promotes T cell proliferation and activation via macrophages, WT and Fats<sup>−/−</sup> BMDMs were incubated with soluble ovalbumin (OVA) overnight and used to activate CD4<sup>+</sup> OT-II and CD8<sup>+</sup> OT-I T cells in vitro. We assessed T cell proliferation 3 days after coculture with WT or Fats<sup>−/−</sup> BMDMs and analyzed the activation of specific T cell subsets by flow cytometry. WT BMDMs only weakly induced the proliferation and activation of antigen-
restricted CD4+ T cells. Conversely, Fats−/− BMDMs significantly induced CD4+ T cell proliferation (CFSF), CD4+ T cell activation (CD69), and the Th1 response (IFN-γ), as indicated by the increases in the population of IFN-γ-producing CD4+ cells (Fig. 6a–c) and protein expression levels of IL-2 and IFN-γ (Fig. 6d). However, FATS deficiency did not influence CD8+ T cell proliferation, as evidenced by the similar CFSE levels in OT-I cells after coculture with LPS-stimulated or LPS-unstimulated Fats−/− or WT BMDMs (Supplementary Fig. 5a). These results were consistent with our previous finding that FATS blockade in macrophages substantially increased the expression of MHCI under M1 polarization conditions (Fig. 4e and Supplementary Fig. 5b). To further verify the effect of Fats−/− macrophages on the adaptive immune system in vivo, WT and Fats−/− BMDMs were transferred into recipient WT mice pre-challenged with B16 cells. The tumor-specific T cell response
within the tumors was analyzed by flow cytometry on day 20. The numbers of both CD4+ and CD8+ T cells were significantly increased (Fig. 6e, f), and IFN-γ expression in both CD4+ T and CD8+ T cells was substantially increased in the tumors of mice transfected with Fats−/− BMDMs but not in those transfected with WT BMDMs (Fig. 6g, h). Together, these results indicated that FATS-deficient macrophages directly promoted CD4+ T cell proliferation and Th1 responses in vivo and in vitro but may indirectly promote CD8+ T cell responses in vivo.

Numerous studies have shown that Th1 cells can generate, augment, and maintain tumor-specific CD8+ CTLs responses. For example, IL-2 secreted by Th1 cells acts as a growth factor for CTLs and functions to recruit CTLs and retain them at the tumor site. IFN-γ production by Th1 cells results in upregulation of MHC molecules on tumor cells, leading to enhanced recognition by T cells (CTLs and Th cells). Therefore, we speculated that the activation of CD8+ T cells in mice adoptively transferred with Fats−/− BMDMs was potentially caused by macrophage-mediated activation of Th1 cells. Collectively, these data further reveal that FATS deficiency stimulates macrophage polarization toward the antitumor phenotype (M1), which has an enhanced capacity to activate Th1 responses.

In addition, we tested the requirement for the adaptive immune system by implanting B16 tumor cells into WT and Fats−/− mice subjected to antibody-mediated depletion of CD4+ or CD8+ T cells. Depletion of either CD4+ or CD8+ T cells partially abrogated the protective effects of FATS deficiency (Fig. 7g). The efficiency of CD4+ T cell depletion (Supplementary Fig. 7a) and CD8+ T cell depletion (Supplementary Fig. 7b) in spleen and tumor tissues was confirmed. However, FATS deficiency did not reduce the tumor burden in the context of CD4+ T cell depletion (Fig. 7g and Supplementary Fig. 7c). CD8+ T cell depletion reversed the inhibition of tumor growth on day 10 but not on day 16 or at later time points in Fats−/− mice (Supplementary Fig. 7c), suggesting that Fats−/− macrophages control tumor growth in a manner mainly dependent on CD4+ T cells. To eliminate the influence of FATS-deficient T cells, we further depleted CD4+ and CD8+ T cells only in WT mice and then transferred these mice with WT BMDMs or Fats−/− BMDMs. As expected, only after CD4+ T cell depletion did the tumor weight in WT mice show no significant change between mice transferred with WT BMDMs and those transferred with Fats−/− BMDMs (Fig. 7h). Moreover, tumor-infiltrating T cells were isolated from B16 tumor-bearing WT or Fats−/− mice, mixed with B16 tumor cells and adoptively transferred into new WT recipient mice. Compared with transfer of tumor-engrafted WT T cells, adoptive transfer of T cells from B16 tumor-bearing Fats−/− mice protected against B16 tumor growth (Fig. 7i). These findings confirm that strategies targeting FATS could enhance T cell-mediated antitumor activity.

FATS deficiency promotes antitumor T cell activity within the TME. To investigate whether FATS deficiency in situ leads to enhanced T cell-mediated antitumor activity within the TME, CD4+ and CD8+ T cell phenotypes were examined in tumor-bearing WT and Fats−/− mice. Consistent with the results from our macrophage adaptive transfer experiment, FATS deficiency significantly increased the percentages and numbers of CD4+ T cells and CD8+ T cells while decreasing the number of regulatory T cells (Tregs) in both B16 and H7 tumors (Fig. 7a, b). The gating strategy for T cell subsets is shown in Supplementary Fig. 1b. FATS deficiency enhanced the expression of CD44, another commonly used marker for T cell activation, on CD4+ T and CD8+ T cells (Fig. 7c). Furthermore, FATS deficiency increased IFN-γ and TNF levels in B16 tumor-infiltrating CD4+ T cells (Fig. 7d), suggesting enhanced Th1 responses. Similarly, FATS deletion increased the expression of Granzyme B and IFN-γ in B16 tumor-infiltrating CD8+ T cells (Fig. 7e), which indicated the positive role of FATS deficiency in CTL activation. PD-1 expression was also increased in CD8+ T cells (Fig. 7f). In addition, in the model of B16 melanoma lung metastasis, pLNs and mLNs were larger in Fats−/− mice than in WT mice (Supplementary Fig. 6a). The percentages of both CD4+ T cells and CD8+ T cells were increased in LNs of Fats−/− mice compared with WT mice (Supplementary Fig. 6b). Moreover, activation of CD4+ T cells and CD8+ T cells was significantly higher in the lungs of Fats−/− mice than in those of WT mice (Supplementary Fig. 6c).

In the future, FATS function will be explored as a potential therapeutic target in other tumor models and other cancers.

**Discussion**

FATS is involved in DNA damage-induced tumorigenesis. Its functional deficit leads to a high frequency of localized deletion events in the genome under replication stress, such as that imposed by IR. Therefore, affected individuals are at increased risk for cancer.
risk of developing tumors caused by chromosomal aberrations. Previous studies demonstrated that FATS functions as a tumor suppressor, since Fats was susceptible to breakage in an IR-induced mouse tumor model and in other types of cancer cells. In the current study, we found that the growth of transplanted tumors (generated from B16 melanoma cells) was significantly inhibited in Fats mice and that the survival of tumor-bearing Fats mice was prolonged. We tried to identify the potential mechanisms accounting for this discrepancy and found a significant change in macrophages between Fats mice.
and WT mice. In addition, we analyzed samples from patients with several types of cancer by using TCGA data (Supplementary Fig. 8), which showed that lower expression of FATS correlated with a higher overall survival rate. These findings encouraged us to further explore the mechanism of FATS in the immune response. Based on our results, we believe FATS may play a role similar to that of immune checkpoints. Specifically, FATS may act as a tumor promoter in the context of immune cell function during cancer development. Furthermore, given that CFSs are an inherent component of chromosomal structure in all individuals and are evolutionarily conserved, they may play a protective role against cancer or other diseases. CFSs preferentially form gaps or breaks on metaphase chromosomes upon replication stress, viral integration, and amplicon induction. Thus, we speculate that in somatic cells, deletion of a fragile site gene usually causes the cells to become cancerous, but at the same time, in immune cells, brittle fracture or lack of a gene locus may spontaneously induce a self-defense system to remove the mutant cells to protect the body; however, this mechanism is just speculative, and subsequent elegantly designed experiments are needed to verify our hypothesis.

In the context of cancer, the host plays important roles in regulating the strength and timing of the anticancer response. The host immune system has the ability to identify and eliminate cancerous/transformed cells. For instance, the risk of developing cancers is increased when the immune system is compromised. Macrophages are essential components of the immune system and are necessary for a protective host defense. However, TAMs are very vulnerable to tumor conditions and adapt to become accomplices (M2 macrophages) of the tumor in vivo at both the primary site and metastatic sites. TAMs can produce growth factors in the TME and participate in intercellular interactions. Based on these findings, we examined the immune profile (particularly focusing on TAMs) of the TME in both WT and Fats−/− mice bearing melanoma tumors. A significant difference was found between WT and Fats−/− mice, as after FATS deficiency, M2-like TAM infiltration into tumors was reduced, while M1-like TAM infiltration was increased. Because M1-like macrophages have good antitumor properties, while M2-like macrophages have the opposite properties, these results further support our hypothesis that FATS-deficient macrophages show antitumor activity. Consistent with these results, the in vitro study indicated that Fats−/− macrophages exhibited an intrinsic bias toward M1 polarization, as evidenced by the high expression of proinflammatory cytokines. In addition, M2 polarization of both BMDMs and peritoneal macrophages from Fats−/− mice was suppressed. The results of transduction of FATS siRNA in human macrophages also confirmed the function of FATS in regulating macrophage polarization. Using the in vivo macrophage adoptive transfer approach, we further proved that Fats−/− macrophages significantly inhibited B16 tumor growth, suggesting that strategies that manipulate macrophage polarization by targeting FATS may be attractive immunotherapies for cancer.

Macrophage polarization is a complex process. It involves the activation of many intracellular signaling pathways. Some studies have pointed out that JNK signaling is required for the polarization of adipose tissue-related macrophages toward an M1-like phenotype. Gene ablation experiments showed that Akt1 and 2 interact to regulate M1 and M2 macrophage polarization. JAK/STAT pathways are also involved in macrophage polarization. It has also been found that metformin can promote M1 macrophages and inhibit M2 macrophages through the Notch signaling pathway, finally inhibiting the growth of liver cancer cells. However, complete polarization of macrophages to the M1 type requires activation of the TLR-4 and IFN-γ signaling pathways. NF-kB is claimed to be the master regulator of inflammation and immunity. Recent studies have indicated that the NF-kB signaling pathway plays an important role in M1 polarization of macrophages, which ultimately leads to significant inhibition of melanoma growth. Consistent with these results, we observed that the NF-kB signaling pathway was significantly activated in Fats−/− macrophages. Blocking NF-kB activity significantly reversed the increases in MHCII and proinflammatory cytokine expression in LPS-stimulated Fats−/− macrophages, indicating that NF-kB activity is involved in FATS-mediated regulation of M1 polarization. NF-kB is reported to be constitutively activated in transformed cells in many kinds of tumors and contribute to cell survival. Treatment with an NF-kB agonist can promote the polarization of macrophages toward the M1 type in tumors and exert antitumor effects, but it can also promote the proliferation and invasion of tumor cells. Therefore, it is important to delete or downregulate FATS expression only in immune cells, a strategy that could effectively avoid this limitation; in other words, NF-kB signaling could be activated in macrophages with no or low FATS expression without promoting tumor cell activation. Furthermore, we found that FATS deficiency sustains NF-kB activity by disrupting NF-kB/IκBα-negative feedback loops and further promotes the polarization of macrophages toward the M1 phenotype.

Moreover, Fats−/− macrophages expressed high levels of MHCII molecules and the costimulatory molecule CD86, thereby exhibiting a more potent antigen presentation function. In addition, Fats−/− macrophages exhibited increased production of IL-12, which promotes the secretion of IFN-γ by T, NK, and NKT cells and induces Th1 responses. An increasing number of studies have reported the crucial role of activated Th1 cells in effective antitumor immunity and infiltration of these cells into tumor tissue is an indicator of more favorable prognosis in pancreatic cancer. Consistent with published results, Fats−/− macrophages promoted the proliferation and activation of CD4+ T lymphocytes and steered them toward the Th1 phenotype.
in vitro. Accordingly, transfer of Fats−/− BMDMs increased the number of CD4+ T cells and promoted Th1 responses. CD4+ Th-derived cytokines are required for full activation of CD8+ T cells, which can give rise to tumor-specific CTLs35,57. This finding may explain why in the in vitro experiment, Fats−/− macrophages did not increase the activation of CD8+ T cells, whereas transfer of Fats−/− BMDMs substantially increased the activation of cytotoxic CD8+ T cells within the tumor. In addition, IFN-γ production by CD4+ Th1 cells further promoted macrophage polarization toward the M1 phenotype, indicating a positive feedback loop in M1 macrophage polarization.

Together, these results indicate that FATS deficiency significantly increases the activation of both macrophage-mediated innate and T cell-mediated adaptive antitumor immune responses while inhibiting immunosuppressive responses, suggesting that FATS may play a role similar to that of immune checkpoints. In this study, we provide evidence for the potential applications of FATS in cancer immunotherapy.
Methods

Cell lines and plasmids. The mouse melanoma cells (B16), pancreatic cancer cells (H7), RAW264.7 cells, and human HEK293T cells were obtained from American Type Culture Collection, and authenticated using short tandem repeat profiling. All cells were cultured in DMEM (Gibco) supplemented with 10% FBS (HyClone) and 1% penicillin–streptomycin (Gibco). All cells were cultured at 37 °C in an atmosphere of 5% CO2 in air. Cells were injected into mice after reaching 60–80% confluence. Myc-IκBα and HA-UB K48 expression constructs were purchased from Vigene Biosciences. The FATS overexpression plasmid was purchased from GeneCopoeia.

Animal care. Female C57BL/6 mice (6–8 weeks old), FATS knockout C57BL/6 mice (Fats−/−), OT-I and OT-II TCR transgenic C57BL/6 mice were maintained under SPF conditions in a controlled environment of 20–22 °C, with a 12/12 h light/dark cycle, 50–70% humidity, and food and water provided ad libitum. C57BL/6 female mice were purchased from the Academy of Military Medical...
Fig. 7 FATS deficiency promotes antitumor T cell activity within the TME. a Phenotypic analysis of tumor-infiltrating T cells after subcutaneous injection of B16 and H7 cells. Total CD3+ CD8+ CD4+, and regulatory T cell (Treg; CD4+ CD25+ Foxp3+) populations among CD45+ cells in B16 tumors (WT n = 10 mice, Fats−/− n = 11 mice for CD3; WT n = 9 mice, Fats−/− n = 7 mice for CD8; WT n = 7 mice, Fats−/− n = 6 mice for CD4; WT n = 5 mice, Fats−/− n = 6 mice for Treg) and H7 tumors (n = 4 mice per group for CD3, CD4; n = 3 mice per group for Treg). b The densities of tumor-infiltrating CD4+ T and CD8+ T cell populations in B16 tumors (n = 3 mice per group). c Flow cytometric analysis and quantification of surface CD44 expression on tumor-infiltrating CD4+ T and CD8+ T cells in B16 tumors (n = 3 mice per group). d Tumor-infiltrating CD4+ T cells were gated and assessed for the expression of IFN-γ (n = 3 mice per group) and TNF (n = 4 mice per group) in B16 tumors. e Tumor-infiltrating CD8+ T cells were gated and assessed for the expression of IFN-γ (n = 3 mice per group) and Granzyme B (n = 5 mice per group) in B16 tumors. f Flow cytometric analysis and quantification of PD-1 expression on tumor-infiltrating CD8+ T cells in B16 tumors (n = 3 mice per group). Data are presented as mean ± s.e.m. in a−f; P values are calculated by two-tailed Student’s t-test in a−f. g CD4+ T or CD8+ T cells were depleted as indicated. The mean tumor volumes in WT and Fats−/− mice are shown. Data are presented as mean ± s.e.m. (n = 6 mice per group; two-way ANOVA). h CD8+ T or CD4+ T cells were depleted in host WT mice. B16 tumor burdens after treatment with WT or Fats−/− macrophages are shown. Data are presented as mean ± s.e.m. (n = 6 mice per group; two-tailed Student’s t-test). i Mean B16 tumor volumes after adoptive transfer of tumor-infiltrating T cells from WT and Fats−/− mice. Data are presented as mean ± s.e.m. (n = 6 mice per group; two-way ANOVA). ns not significant. All tumor samples were collected on day 20 (melanoma) or day 30 (pancreatic cancer) after tumor cell implantation. Source data are provided as a Source Data file.

T cell suppression assay. Spleens from WT mice were isolated and passed through 40 μm filters to generate a single-cell suspension. After red blood cell lysis, CD3+ T cells were purified using CD3 microbeads (Miltenyi Biotech) according to the manufacturer’s protocol and labeled with 2.5 μM CFSE (Invitrogen) for 10 min at 37°C. The labeled CD3+ T cells were intensively washed with PBS and were then plated in complete RPMI medium supplemented with 0.05 M β-mercaptoethanol in round-bottom 96-well plates (1 × 105 cells per well) coated with 5 μg/ml anti-CD3 (Invitrogen, 16-0331-86) and 2 μg/ml anti-CD28 (Invitrogen, 16-0281-85) antibodies. Purified TAMS (CD11b+ F4/80+) prepared as described above were added at the indicated ratios, and the plates were incubated at 37°C. After 72 h, the cells were harvested, and the CFSE signal in the gated CD3+ T cell population was measured by flow cytometry.

Cell depletion experiments. WT and Fats−/− female mice treated with or without i.v. injection of 1 mg/mouse clodronate liposomes or PBS liposomes (Clodronate Liposomes.com, Amsterdam, The Netherlands) were used for in vivo macrophage depletion experiments. Treatment started one day before challenge with B16 tumor cells and continued every 4 days (Q4D) during the study. Tumor measurements were performed every 2 days. When the average volume of the tumors was 2500 mm3, mice were euthanized, tumor tissues were collected, and tumor-infiltrating mononuclear cells were isolated and analyzed as mentioned above. For in vivo depletion of CD4+ T or CD8+ T cells, 200 μg anti-CD4 (Sungeone, clone: GK1:5) or anti-CD8a (Sungeone, clone: 53-6.7) antibodies was injected intraperitoneally beginning 1 day before tumor implantation and continuing every 4 days (Q4D) for the duration of the study. Control animals were injected intraperitoneally with isotype control antibody (Sungeone, clone: MIP-1) on the same dosing schedule. CD4+ or CD8+ T cell depletion was verified by flow cytometric analysis of spleens and tumor tissues.

Peritoneal macrophage isolation. Peritoneal macrophages were harvested in 5 ml of PBS from the mouse peritoneal cavity 72 h after intraperitoneal injection of 3% thioglycollate solution. After washing with PBS, cells were cultured in RPMI medium supplemented with 10% FBS and 1% pen/strep for 2 h at 37°C in 5% CO2. After 2 h, nonadherent cells were removed by washing three times with PBS, and cells were analyzed via flow cytometry or Quantitative Real-time PCR or were stimulated with LPS and analyzed by immunoblotting. The purity of CD11b+ F4/80+ cells was verified to be 98% by flow cytometry. In some studies, peritoneal macrophages were preincubated with an inhibitor of NF-κB (BAY11-7082, 5 μM, MCE) for 2 h prior to the addition of polarizing stimuli.

Mouse macrophage differentiation. Bone marrow-derived cells were aseptically harvested from 6- to 8-week-old female mice by flushing the femurs and tibias of euthanized mice. Red blood cells were solubilized with red cell lysis buffer (Solarbio), and the remaining cells were cultured in RPMI medium supplemented with 10% foetal calf serum (FCS) (PeproTech, 315-02) for 6 days; fresh medium was added on day 3. The purity of CD11b+ F4/80+ macrophages was verified to be 95% by flow cytometry.
Human macrophage differentiation. Fresh human buffy coat blood was obtained from Tianjin Blood Center (Tianjin, China). Ethical consent was obtained by the Tianjin blood center and samples were anonymised before use. Ficoll-Paque PLUS (GE Healthcare Biosciences AB, 17-0891-09) was used to isolate peripheral blood mononuclear cells (PBMCs). Cells were centrifuged at 400 × g for 30 min and washed with PBS three times to obtain PBMCs. CD14+ monocytes were isolated from PBMCs using CD14 MicroBeads (Miltenyi Biotec, 130-050-201) according to the manufacturer’s instructions. Purified CD14+ monocytes were analyzed using flow cytometry to ensure their purity (>95%). Primary CD14+ cells were incubated with 50 ng/ml recombinant human M-CSF (PeproTech, 300-25) for 6 days, and fresh medium was added on day 3.

Macrophage polarization. To induce M1-like polarization, bone marrow-derived cells (BMDCs) were stimulated with recombinant murine GM-CSF (PeproTech, 300-25) for 6 days followed by IFN-γ (Sigma, 20 ng/ml) and LPS (Sigma, 100 ng/ml) for 24 h. To induce M2-like polarization, BMDCs were incubated with M-CSF (PeproTech, 10 ng/ml) for 6 days followed by IL-4 (PeproTech, 20 ng/ml) and IL-10 (PeproTech, 20 ng/ml) for 24 h. For inhibitor studies, macrophages were incubated with BAY11-7082 (MCE, 5 μM) for 2 h prior to the addition of polarizing stimuli. Cells were harvested and analyzed by Quantitative Real-time PCR or flow cytometry.

Gene silencing and transfection. Macrophages prepared as described above were transfected with 20 nM targeting siRNA or nontargeting control siRNA (NC-siRNA) using Lipofectamine RNAiMAX Reagent according to the manufacturer’s instructions (Invitrogen). siRNAs targeting mouse Fats (5′-
Fig. 8 FATS is a potential target for tumor immunotherapy. a Schematic of the BMDMs adoptive transfer experiment. b-d Representative image (n = 5 mice per group), tumor volumes (n = 7 mice per group; two-way ANOVA) and quantitative analysis of the weights (n = 7 mice per group; two-tailed Student’s t-test) of B16 tumors in recipient WT mice treated without (None) or with WT BMDMs (WT M-T cell adoptive transfer) and the efficiency of siRNA was confirmed (n = 3 biologically independent samples). g, h Tumor volumes (n = 6 mice per group; two-way ANOVA) and quantitative analysis of the tumor weights in recipient WT mice treated without (None) or with BMDMs transfected with NC siRNA (NC-siRNA M-T cell adoptive transfer) on day 20. e Schematic of the siRNA-transfected BMDMs adoptive transfer experiment. BMDMs treated with nontargeting control (NC) or Fats siRNA were intravenously injected into recipient WT mice on day 1 and day 9 separately. f The relative mRNA level of Fats was measured by Quantitative Real-time PCR, and the efficiency of siRNA was confirmed (n = 3 biologically independent samples). g, h Tumor volumes (n = 6 mice per group; two-way ANOVA) and quantitative analysis of the tumor weights in recipient WT mice treated without (None) or with BMDMs transfected with NC siRNA (NC-siRNA M-T cell adoptive transfer) on day 20. The data are representative of two independent experiments with similar results. I Model depicting the effect of FATS deficiency on tumor immune stimulation. FATS signaling in macrophages inhibits the activation of NF-κB and an immunosuppressive M2-like state featuring abundant secretion of inhibitory cytokines and suppression of CD4+ and CD8+ T cell activation (left panel). By contrast, FATS deficiency promotes the NF-κB activation and shifts macrophage polarization toward an M1-like phenotype characterized by higher antigen presentation capability and secretion of numerous proinflammatory cytokines; this phenotype further promotes the proliferation of CD4+ T cells and induces Th1 responses, which in turn promote CD8+ T cell priming and thereby enhances antitumor immunity (right panel). Data are presented as mean ± s.e.m. in c, d, f-h. ns not significant. Two independent experiments were carried out with similar results in a-d. Source data are provided as a Source Data file.

**In vivo macrophage adoptive transfer experiment.** A total of 2 × 10^5 B16 tumor cells were injected subcutaneously into WT mice on day 0 of the experiment. Primary BMDMs were harvested from donor WT and Fats−/− mice and prepared into a single-cell suspension. On day 1 of the experiment, purified BMDMs (5 × 10^5 cells per mouse) were injected intravenously into B16 cell-challenged host WT mice. On day 9 after tumor cell implantation, B16 cell-challenged host WT mice received the second macrophage adoptive transfer treatment administered via the same protocol as the first treatment. Tumor dimensions were measured three times per week beginning on day 7.

**T cell adoptive transfer.** WT and Fats−/− mice were implanted with 2 × 10^5 B16 tumor cells by subcutaneous injection. On day 18 after tumor cell implantation, tumor-infiltrated T cells were isolated by flow sorting and mixed 1:1 with B16 tumor cells, and a total of 5 × 10^6 cells were injected subcutaneously into new recipient WT mice. Tumor growth was monitored for up to 20 days.

**BMDM antigen presentation and cross-presentation assay.** BMDMs or without LPS treatment were preincubated with 0.5 mg/ml soluble OVA overnight prior to the addition of prelabeled OT-I or OT-II splenocytes at a BMDM:T cell ratio of 1:4. The proliferation of OT-I or OT-II T cells was assessed by flow cytometry after 72 h. To further detect the ability of BMDMs to induce MHC-II-specific activation of CD4+ T cells, cocultured OT-II CD4+ T cells were stimulated with 50 ng/ml PMA and 1 μM ionomycin for 4 h in the presence of 5 μg/ml brefeldin A before being harvested and assessed by flow cytometry to detect CD25 expression and IFN-γ production. At the same time, the content of cytokines in the supernatant was assessed by enzyme-linked immunosorbent assay (ELISA).

**Cytokine measurement.** Peripheral blood was collected from WT and Fats−/− tumor bearing mice 20 days after subcutaneous implantation of B16 cells and allowed to clot for 1–2 h. Serum was separated by centrifugation at 1800 × g for 10 min. In other experiments, BMDMs were stimulated with LPS (100 ng/ml) or IL-4 (20 ng/ml) for 24 h or were left untreated. Macrophage supernatants were collected. Cytokine levels in the above-mentioned serum or supernatants were measured using Bio-Plex Pro Mouse Cytokine & Chemokine Assay Kits (Bio-Rad) according to the manufacturer’s instructions. Additionally, the supernatants of BMDMs cocultured with OT-II CD4+ T cells were collected after 72 h, and mouse IFN-γ and IL-2 ELISA Kits (Multi Sciences) were used to detect the contents of IFN-γ and IL-2 according to the manufacturer’s instructions.

**RNA sequencing.** Freshly isolated mouse bone marrow cells from four WT and four Fats−/− mice were pooled into one replicate set of each WT and Fats−/− cells and were fully differentiated into macrophages in RPMI containing 10% FBS, 1% pen/strep, and 10 ng/ml M-CSF for 6 days. BMDMs were removed from the dishes, and RNA was harvested using a Qiagen Allprep kit. RNA libraries prepared from 1 μg of RNA per sample were prepared for sequencing using standard Illumina protocols. RNA sequencing was performed by GENEWIZ. mRNA profiles were generated by single-end deep sequencing using the Illumina HiSeq 2000 platform.

**Sequence analysis.** Sequence files obtained from the Illumina HiSeq platform that passed quality filtering were aligned to the mouse transcriptome (mm9 build) using the Bowtie2 aligner. Gene-level count summaries were analyzed for significant changes using DESeq. Individual P values were adjusted for multiple testing by calculating q values as described by Storey with fdrtooltrimmer. For a given gene, the q value is the smallest false discovery rate at which the gene can be considered significant. We analyzed biological processes that are defined by the Gene Ontology Consortium. Each gene ontology term defines a set of genes. The entire list of genes, sorted by the q value in ascending order, was subjected to a nonparametric variant of gene set enrichment analysis (GSEA), in which the parametric Kolmogorov–Smirnov P value was replaced with the exact rank order P value. We applied the Bonferroni adjustment to gene set P values to correct for the number of gene sets tested. Heatmaps of expression levels were generated using in-house hierarchical clustering software that implements Ward clustering. The colors qualitatively correspond to fold changes.

**Quantitative Real-time PCR.** Total RNA was extracted with TRIzol (Invitrogen) from the indicated cells. CDNA was prepared from 2 μg of RNA with a M-MLV Reverse Transcriptase cDNA Synthesis Kit (Invitrogen). SYBR Green-based qPCR was performed using primers for human and mouse Arg1, Mr1, Tgfβ, and Il10 and for mouse Il1b, Il12a, Il12b, Il6, Ifng, Gmcsf, Tnf, Nos2, Cita, H2e2b, and Ym1. mRNA levels were normalized to that of Gapdh (GAPD = ct gene of interest–ct GAPDH) and are reported as relative mRNA expression (2^−ΔΔct sample–GAPDH control) or fold change values. Primer information is listed in Supplementary Table 1.

**Western blot analysis.** The whole-cell lysates were prepared using RIPA lysis buffer in the presence of 1% phosphatase inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride (PMSF). A total of 20–30 μg of protein was denatured and electrophoresed on Bio-Rad precast gradient gels and transferred to a PVDVF membrane (Millipore, USA). After blocking with 5% non-fat milk at room temperature for 1 h, the membranes were incubated with primary antibodies (1:1000 dilution) overnight at 4°C. The membrane was then incubated with horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology, 1:5000) and immunoreactive bands were visualized using the ECL Western Blotting Detection System (Millipore, USA). Antibody information is listed in Supplementary Table 2.

**Co-immunoprecipitation analysis.** Co-IP analysis was performed in accordance with standard procedures. Lysates from 1 × 10^7 cells transfected with the indicated constructs were incubated with 30 μl of Flag-conjugated agarose beads (Sigma-Aldrich, M8823) overnight at 4°C. Beads containing affinity-bound proteins were washed six times and were then eluted with 50 μl of 2× sample buffer, and the eluates were boiled in a water bath (100°C) for 10 min. The collected proteins were separated on SDS-polyacrylamide gels and subjected to western blot analysis using anti-myc (Proteinteck, 16286–1-AP, 1:4000), anti-HA (Proteinteck, 51062–2-AP, 1:3000), and anti-Flag (Sigma-Aldrich, F3165, 1:2000) antibodies.
Ubiquitination assays. Ubiquitination assays were performed in accordance with the following standard procedures: Myc-tagged Indo and HA-Ub K48 were overexpressed in HEK293T cells (1 × 10^7 cells) in the indicated group. Cell lysates were incubated with 30 μl of Myc-conjugated agarose beads (Sigma-Aldrich, E65654) overnight at 4 °C. Beads containing affinity-bound proteins were washed six times and were then eluted with 50 μl of 2x sample buffer, and the eluates were boiled in a water bath (100 °C) for 10 min. The collected proteins were separated on SDS-polyacrylamide gels and subjected to western blot analysis using anti-HA (ProteinTech, 51064-2-AP, 1:3000) and anti-Myc (ProteinTech, 16286-1-AP, 1:4000) antibodies.

Immunofluorescence. WT and Fats−/− BMDMs were grown on chamber slides (BD Discovery Labware, Bedford, MA) in complete RPMI medium for 24 h at 37 °C. Cells were treated with or without LPS at 100 ng/ml for 30 or 60 min. Immediately after LPS treatment, cells were washed with ice-cold PBS twice and were then fixed with 4% paraformaldehyde/PBS for 15 min, permeabilized with 0.2% Triton X-100/PBS for 20 min, and preblocked in 5% BSA/PBS overnight. Slides were then incubated with a rabbit anti-p65 antibody (Cell Signaling Technology, #8242, 1:100) in blocking solution overnight at 4 °C. The next day, slides were washed three times with PBS and incubated with FITC-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, 111-095-003, 1:200) at room temperature in the dark for 1 h. After washing with PBS, slides were counterstained with 4',6-diamidino-2-phenylindole (DAPI) to identify nuclei. Immunofluorescence images were acquired with an upright fluorescence microscope (OLYMPUS BX51) and analyzed by ImageJ.

Bioinformatics analysis. Kaplan–Meier plotter (https://kmplot.com)39 was used to assess the correlation between FATS expression and overall survival of kidney renal clear cell carcinoma patients, kidney renal papillary cell carcinoma patients, stomach adenocarcinoma patients, uterine corpus endometrial carcinoma patients, and liver hepatocellular carcinoma patients. We analyzed TCGA data for association between FATS expression and overall survival of the skin cutaneous melanoma patients. Illumina HiSeq RNAseqV2 mRNA expression and clinical data for 488 skin cutaneous melanoma samples were downloaded from the TCGA data portal. We scored subjects as above (high) or below (low) the median expression level.

For the expression analysis of 488 skin cutaneous melanoma samples, we downloaded from the TCGA data portal.

Received: 5 June 2020; Accepted: 23 June 2021; Published online: 14 July 2021

References
1. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, in inflammation, and cancer. Cell 140, 883–899 (2010).
2. Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904–5912 (2008).
3. Di Martile, M. et al. Melanoma-specific beta-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. J. Immunother. Cancer 8, e000489 (2020).
4. Mantovani, A., Sica, A. & Locati, M. Macrophage polarization comes of age. Immunity 23, 344–346 (2005).
5. Solnas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) as a major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065–1073 (2009).
6. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78 (2004).
7. Condeelis, J. & Pollard, J. W. Macrophage-obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263–266 (2006).
8. Liu, Y. & Cao, X. Immunosuppressive cells in tumor immune escape and metastasis. J. Mol. Med. (Berl.) 94, 509–522 (2016).
9. Jayasangam, S. D. et al. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissues: technicalities and challenges in routine clinical practice. Front. Oncol. 9, 1512 (2019).
10. Zeisberger, S. M. et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95, 272–281 (2006).
11. Misulis, N. R., Wu, Z., Van Rooijen, N. & Kane, A. B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 7, 788–799 (2008).
12. Anfray, C., Ummarino, A., Andon, F. T. & Allavena, P. Current strategies to target tumor-associated macrophages to improve anti-tumor immune responses. Cells 9, 46 (2020).
13. Kaneda, M. M. et al. PISKy is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
14. Cieslewicz, M. et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc. Natl Acad. Sci. USA 110, 15919–15924 (2013).
15. Costea, M. et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell. Mol. Med. 14, 2803–2815 (2010).
16. Rolny, C. et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PGE2. Cancer Cell 19, 31–44 (2011).
17. Pentzold, C. G. et al. FAKNCD2 binding identifies conserved fragile sites at large transcribed genes in avian cells. Nucleic Acids Res. 46, 1280–1294 (2018).
18. Sarni, D. & Kerem, B. The complex nature of fragile site plasticity and its importance in cancer. Curr. Opin. Cell Biol. 40, 131–136 (2016).
19. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
20. Re, A., Cora, D., Puliti, A. M., Caselle, M. & Brana, I. Correlated fragile site expression allows the identification of candidate fragile genes involved in immunity and associated with carcinogenesis. BMC Bioinformatics 7, 413 (2006).
21. Li, Z. et al. An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. Oncogene 29, 2659–2671 (2010).
22. Tian, Y., Zhang, J., Yan, S., Qiu, L. & Li, Z. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer. Lung Cancer (Amst., Neth.) 76, 416–422 (2012).
23. Zhang, J. et al. Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer. Chin. Med. J. 124, 2894–2898 (2011).
24. Zhang, X. et al. FATS is a transcriptional target of p53 and associated with antimacrophage activity. Mol. Cancer 9, 244 (2010).
25. Ostuni, R., Kratochvil, F., Murray, P. J. & Natoli, G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 36, 229–239 (2015).
26. van Rooijen, N., Kors, N., ter Hart, H. & Claasen, E. In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate. Virchows Arch. B Pathol. Incl. Mol. Pathol. 54, 241–245 (1988).
27. Yamamoto, M. et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4, 1144–1150 (2003).
28. Bode, J. G., Ehlting, C. & Häussinger, D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell. Signal. 24, 1185–1194 (2012).
29. Hu, J., Nakano, H., Sakurai, H. & Kolbarn, N. H. Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant J68 cells. Carcinogenesis 25, 1991–2003 (2004).
30. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-kB as the matchmaker. Nat. Immunol. 12, 715–723 (2011).
31. Yan, S. et al. FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes its activation in response to DNA damage. Oncogene 33, 5424–5433 (2014).
32. Traenckner, E. B. & Baeuerle, P. A. Appearance of apparently ubiquitin-conjugated 1 kappa B-alpha during its phosphorylation-induced degradation in intact cells. J. Cell Sci. Suppl. 19, 79–84 (1995).
33. Mills, C. D., Lenz, L. L. & Harris, R. A. A breakthrough: macrophage-directed cancer immunotherapy. Cancer Res. 76, 513–516 (2016).
